{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:19:15Z","timestamp":1782832755327,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2024.01.010","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T04:25:29Z","timestamp":1705811129000},"page":"S86-S89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S1","title":["Dyslipidemia and peripheral arterial disease"],"prefix":"10.1016","volume":"76","author":[{"given":"Ajay","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Singh Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanupriya","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ihj.2024.01.010_bib1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40265-022-01755-7","article-title":"Current management of peripheral artery disease: focus on pharmacotherapy","volume":"82","author":"Golledge","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ihj.2024.01.010_bib2","first-page":"111","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias : lipid modification to reduce cardiovascular risk","author":"Society","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ihj.2024.01.010_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ihj.2017.11.001","article-title":"Prevalence of peripheral artery disease and risk factors in the elderly: a community based cross-sectional study from northern Kerala, India","volume":"70","author":"Krishnan","year":"2018","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2024.01.010_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007385","article-title":"Polyvascular disease: reappraisal of the current clinical landscape","volume":"12","author":"Gutierrez","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ihj.2024.01.010_bib5","series-title":"The World Health Report 2002: Reducing Risks, Promoting Healthy Lives","year":"2002"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.010_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1875-2136(08)70263-8","article-title":"REACH: international prospective observational registry in patients at risk of atherothrombotic events Results for the French arm at baseline and one year","volume":"101","author":"Mas","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ihj.2024.01.010_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence recognition, and treatment of cardiovascular risk factors in outpatients with Atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2024.01.010_bib8","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2024.01.010_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ihj.2024.01.010_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM199202063260605","article-title":"Mortality over a period of 10 years in patients with peripheral arterial disease","volume":"326","author":"Criqui","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2024.01.010_bib11","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS Guidelines for management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2024.01.010_bib12","doi-asserted-by":"crossref","first-page":"926","DOI":"10.33963\/KP.14945","article-title":"The prevalence of polyvascular disease in patients with carotid artery disease and peripheral artery disease","volume":"77","author":"Vlajinac","year":"2019","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.ihj.2024.01.010_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.04.015","article-title":"Asymptomatic polyvascular disease and the risks of cardiovascular events and all-cause death","volume":"262","author":"Zhang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ihj.2024.01.010_bib14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.acvd.2010.02.002","article-title":"Impact of polyvascular disease on baseline characteristics, management and mortality in acute myocardial infarction","volume":"103","author":"Meizels","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ihj.2024.01.010_bib15","article-title":"Lipid-lowering for peripheral arterial disease of the lower limb","volume":"4","author":"Aung","year":"2007","journal-title":"Cochrane Database Syst"},{"key":"10.1016\/j.ihj.2024.01.010_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2021.09.022","article-title":"Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease: European atherosclerosis society\/European society of vascular medicine joint statement","volume":"338","author":"Belch","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ihj.2024.01.010_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejvs.2004.07.008","article-title":"A combination of statins and beta-blockers is associated with a reduction in the incidence of perioperative mortality in nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery","volume":"28","author":"Kertai","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ihj.2024.01.010_bib19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jvs.2004.01.004","article-title":"Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial","volume":"39","author":"Durazzo","year":"2004","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ihj.2024.01.010_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMoa0808207","article-title":"Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Fluvastatin and perioperative events in patients undergoing vascular surgery","volume":"361","author":"Schouten","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2024.01.010_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.amjcard.2007.02.093","article-title":"Effect of statin withdrawal on frequency of cardiac events after vascular surgery","volume":"100","author":"Schouten","year":"2007","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ihj.2024.01.010_bib22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/ejvs.2002.1611","article-title":"The early effect of lipid lowering treatment on carotid and femoral intima media thickness (IMT)","volume":"23","author":"Youssef","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ihj.2024.01.010_bib23","first-page":"e1","article-title":"The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design","volume":"151","author":"Ohman","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"9346","key":"10.1016\/j.ihj.2024.01.010_bib24","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ihj.2024.01.010_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in people with peripheral arterial disease and other high-risk conditions","volume":"45","author":"Group","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ihj.2024.01.010_bib16","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"Heart protection study cholesterol lowering, collaborative group. MRC\/BHF heart protection study of placebo controlled, with simvastatin in 5963 people with diabetes: a randomised trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2024.01.010_bib26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ihj.2024.01.010_bib27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/1358863X18796936","article-title":"Polyvascular disease and risk: when two is not better than one","volume":"23","author":"Bonaca","year":"2018","journal-title":"Vasc Med"},{"key":"10.1016\/j.ihj.2024.01.010_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.ihj.2024.01.010_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2024.01.010_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2024.01.010_bib31","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.120.046524","article-title":"Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modifica- tion by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"141","author":"Schwartz","year":"2020","journal-title":"Circulation"},{"issue":"9500","key":"10.1016\/j.ihj.2024.01.010_bib32","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Field","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ihj.2024.01.010_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.ihj.2024.01.010_bib34","first-page":"2851","article-title":"ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries","author":"Tendera","year":"2011","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ihj.2024.01.010_bib35","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"REDUCE-IT investigators. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ihj.2024.01.010_bib36","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12325-019-01211-1","article-title":"Critical differences between dietary supplement and prescription omega-3 fatty acids: a narrative review","volume":"37","author":"Hilleman","year":"2020","journal-title":"Adv Ther"},{"issue":"15","key":"10.1016\/j.ihj.2024.01.010_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ihj.2024.01.010_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"ORION-10 and ORION-11 investigators. Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483224000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483224000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:38:38Z","timestamp":1712626718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483224000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":38,"alternative-id":["S0019483224000105"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.010","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyslipidemia and peripheral arterial disease","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}